Skip to content
stoqly

Ionis Pharmaceuticals Inc

IONS Nasdaq Pharmaceutical Preparations Financials FY2016–FY2025

Revenue Total sales reported in the income statement.
$944M
33.8% vs prior year
Operating margin Operating income as a share of revenue.
−40.4%
26.9 pts
Net income Profit after all expenses, interest and tax.
−$381M
Free cash flow Cash from operations minus capital spending.
−$320M
Return on capital After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
—
Market cap Last close times the latest diluted share count, so it is approximate.
—
P/E Last close divided by diluted earnings per share over the last four quarters.
—
On −$3.46 EPS (TTM)

What Ionis Pharmaceuticals Inc does

No business description yet.

Legal name
IONIS PHARMACEUTICALS INC
Fiscal year ends
December 31, 2025
Latest annual report
10-K · Feb 26, 2026
Accession · CIK
0000874015-26-000115
0000874015

Revenue and margins

Ionis Pharmaceuticals Inc had $944M of revenue in fiscal 2025, up 33.8% on the year before.

Revenue
Revenue
Margins, % of revenue
Gross Operating Net FCF
Margins, % of revenue
Gross Operating Net FCF

Net income and earnings per share

Loss periods are shown in red.

Net income
Net income
Diluted EPS
Diluted EPS

Returns on capital

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

Return on capital, equity and assets (annual)
Return on capital Return on equity Return on assets

Cash flow

Free cash flow was −$320M in fiscal 2025, −33.9% of revenue. Cash from operations minus capital spending.

Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations Capital spending
Cash from operations vs capital spending
Cash from operations Capital spending

Dividends, buybacks and share count

Ionis Pharmaceuticals Inc returned — to shareholders in fiscal 2025. The diluted share count rose 7.0%.

Dividends and buybacks
Dividends Buybacks
Diluted shares outstanding (annual)

Balance sheet

Cash, debt and the ratios that show how comfortably Ionis Pharmaceuticals Inc can carry it.

Cash vs debt (incl. leases)
Cash Debt
Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments $2.1B$2.0B$2.3B$2.3B$2.7B
Debt incl. finance leases —$1.2B$1.3B$1.3B$1.8B
Debt / equity —2.1x3.4x2.1x3.7x
Interest coverage −3.2x−50.5x−27.9x−28.0x−22.1x
Current ratio 9.7x7.1x5.9x8.5x3.8x
Quick ratio 9.6x7.0x5.9x8.4x3.8x
Total assets $2.6B$2.5B$3.0B$3.0B$3.5B
Total liabilities $1.8B$2.0B$2.6B$2.4B$3.0B
Shareholders' equity $772M$573M$387M$588M$489M
Net debt (− = net cash) —−$793M−$1.0B−$1.0B−$865M

Insider trades

Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.

Bought, 12 months

$0.0M

0 insiders

Sold, 12 months

$0.0M

0 insiders

Of sales under plans

—

$0.0M

No open-market insider trades in the last 12 months.

Piotroski F-score

Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.

TestFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Net income is positive ✕ ✓ ✓ ✓ ✕ ✕ ✕ ✕ ✕ ✕
Cash from operations is positive ✕ ✓ ✓ ✓ ✓ ✓ ✕ ✕ ✕ ✕
Return on assets rose — ✓ ✓ ✕ ✕ ✓ ✕ ✕ ✕ ✓
Cash from operations exceeds net income ✕ ✓ ✓ ✓ ✓ ✓ ✕ ✓ ✕ ✓
Debt fell relative to assets — ✓ ✕ ✕ ✕ — — ✓ ✓ ✕
Current ratio rose — ✕ ✓ ✓ ✕ ✓ ✕ ✕ ✓ ✕
Share count didn't rise — ✕ ✕ ✕ ✓ ✕ ✕ ✕ ✕ ✕
Gross margin rose — ✕ ✕ ✕ ✕ ✓ ✕ ✓ ✕ ✕
Revenue rose relative to assets — ✓ ✕ ✓ ✕ ✓ ✕ ✓ ✕ ✓
F-score — / 36 / 95 / 95 / 93 / 96 / 80 / 84 / 92 / 93 / 9
Accruals ratio 5.7%−15.6%−16.5%−2.3%−17.1%−2.4%0.2%−2.1%1.6%−3.5%
Altman Z'' 0.532.004.156.012.654.202.282.221.801.12

10 years of figures

US$ millions unless stated. Hover a ratio's name for its definition.

Download CSV
Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue $347M $508M $600M $1.1B $729M $810M $587M $788M $705M $944M
Gross profit $347M $508M $598M $1.1B $717M $800M $573M $779M $694M $928M
Research and development $340M $373M $412M $462M $531M $638M — $900M $902M $916M
Operating income −$20.2M $31.0M −$61.4M $366M −$172M −$30.2M −$410M −$354M −$475M −$382M
Interest expense $38.8M $44.8M $44.8M $12.4M $9.5M $9.3M $8.1M $12.7M $17.0M $17.3M
Pretax income −$83.6M −$16.8M −$76.2M $339M −$135M −$29.1M −$258M −$334M −$460M −$380M
Income tax $2.9M −$6.0M −$291M $51.5M $345M −$0.6M $11.7M $32.3M −$6.2M $1.8M
Net income −$60.4M $0.3M $274M $278M −$444M −$28.6M −$270M −$366M −$454M −$381M
Net income to common — $18.8M $277M $281M −$444M — — — — —
Diluted EPS −$0.50 $0.15 $2.07 $1.90 −$3.18 −$0.20 −$1.90 −$2.56 −$3.04 −$2.38
Diluted shares 0.12B 0.13B 0.13B 0.15B 0.14B 0.14B 0.14B 0.14B 0.15B 0.16B
Cash flow
Cash from operations −$112M $174M $603M $346M $35.9M $30.8M −$274M −$308M −$501M −$269M
Capital expenditure $7.1M $34.8M $13.6M $30.9M $35.1M $12.0M $15.7M $23.8M $45.3M $51.4M
Free cash flow −$119M $139M $589M $315M $0.8M $18.8M −$290M −$331M −$546M −$320M
Depreciation and amortization $7.5M $6.7M $10.7M $12.5M $13.4M $15.5M $14.3M $10.3M $9.6M $10.0M
Stock-based compensation $72.1M $86.0M $131M $147M $230M $121M $100M $106M $130M $134M
Share buybacks — $0.0M $0.0M $34.4M $90.5M $0.0M $0.0M — — —
Dividends and buybacks — $0.0M $0.0M $34.4M $90.5M $0.0M $0.0M — — —
Balance sheet
Cash and short-term investments $665M $1.0B $2.1B $2.5B $1.9B $2.1B $2.0B $2.3B $2.3B $2.7B
Total debt $1.2M $1.6M $13.7M $788M $840M — $1.2B $1.3B $1.3B $1.8B
Current assets $798M $1.2B $2.2B $2.7B $2.1B $2.3B $2.2B $2.6B $2.6B $3.0B
Current liabilities $134M $244M $280M $273M $599M $241M $312M $448M $309M $782M
Inventory — $10.0M $8.6M $18.2M $22.0M $24.8M $22.0M $7.4M $12.5M $10.0M
Property and equipment, net $92.8M $122M $132M $154M $181M $178M $74.3M $71.0M $94.3M $123M
Intangible assets $20.4M $22.0M $24.0M $25.7M $27.9M $29.0M — — — —
Total assets $912M $1.3B $2.7B $3.2B $2.4B $2.6B $2.5B $3.0B $3.0B $3.5B
Total liabilities $813M $957M $1.5B $1.5B $1.6B $1.8B $2.0B $2.6B $2.4B $3.0B
Shareholders' equity $99.6M $281M $1.0B $1.5B $743M $772M $573M $387M $588M $489M
Margins
Gross margin 100.0% 100.0% 99.7% 99.6% 98.4% 98.7% 97.6% 98.8% 98.4% 98.3%
Operating margin −5.8% 6.1% −10.2% 32.6% −23.6% −3.7% −69.8% −44.9% −67.4% −40.4%
EBITDA margin −3.7% 7.4% −8.4% 33.7% −21.8% −1.8% −67.4% −43.6% −66.0% −39.4%
Net margin −17.4% 0.1% 45.6% 24.8% −60.9% −3.5% −45.9% −46.5% −64.4% −40.4%
FCF margin −34.4% 27.5% 98.3% 28.0% 0.1% 2.3% −49.4% −42.1% −77.5% −33.9%
Returns
Return on capital employed −2.6% 2.9% −2.6% 12.4% −9.6% −1.3% −18.5% −13.9% −17.6% −13.9%
Return on equity −60.7% 0.2% 41.2% 22.1% −40.1% −3.8% −40.1% −76.3% −93.1% −70.8%
Return on assets −6.6% 0.0% 13.7% 9.4% −15.8% −1.1% −10.5% −13.3% −15.1% −11.7%
Return on tangible equity −76.3% 7.3% 27.0% 19.4% −62.1% −3.9% −47.1% −94.7% −77.1% −78.0%
Growth
Revenue growth — 46.5% 18.1% 87.2% −35.0% 11.1% −27.5% 34.1% −10.5% 33.8%
Net income growth — — 79,015.9% 1.6% −259.7% — — — — —
EPS growth — — 1,280.0% −8.2% −267.4% — — — — —
FCF growth — — 322.8% −46.6% −99.8% 2,340.9% −1,639.4% — — —
Share count change — 4.3% 6.3% 14.3% −8.8% 1.0% 0.6% 0.9% 4.4% 7.0%
Financial health
Net debt / EBITDA — −27.0x — −4.5x — — — — — —
Debt / equity 0.0x 0.0x 0.0x 0.5x 1.1x — 2.1x 3.4x 2.1x 3.7x
Interest coverage −0.5x 0.7x −1.4x 29.4x −18.1x −3.2x −50.5x −27.9x −28.0x −22.1x
Current ratio 6.0x 4.8x 7.9x 10.0x 3.6x 9.7x 7.1x 5.9x 8.5x 3.8x
Quick ratio 6.0x 4.8x 7.8x 9.9x 3.5x 9.6x 7.0x 5.9x 8.4x 3.8x
Capital allocation
Capex / revenue 2.1% 6.8% 2.3% 2.8% 4.8% 1.5% 2.7% 3.0% 6.4% 5.5%
Stock comp / revenue 20.8% 16.9% 21.9% 13.1% 31.6% 14.9% 17.1% 13.4% 18.5% 14.2%
Payouts / FCF — 0.0% 0.0% 10.9% 11,729.0% 0.0% — — — —
Quality scores
Piotroski F-score — 6.0 5.0 5.0 3.0 6.0 0.0 4.0 2.0 3.0
Altman Z'' 0.5 2.0 4.1 6.0 2.7 4.2 2.3 2.2 1.8 1.1
Accruals ratio 5.7% −15.6% −16.5% −2.3% −17.1% −2.4% 0.2% −2.1% 1.6% −3.5%

Source: SEC EDGAR XBRL filings (CIK 0000874015). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.

↑ ↓ to move · ↵ to open